These therapies must not be antagonistic and ideally should exert synergist effects targeting concomitant abnormal cellular and molecular pathways that drive its pathogenesis (thereby expanding the biological response) and prevent compensatory pathways that can reduce the efficacy of a single drug [6, 9, 132]
High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization
Verspohl EJ: Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
Progressive potency loss The first thing that happens is a gradual loss of active peptide
Based on the current evidence, it looks serious
Haemoglobin levels begin to rise after about one week, whilst the mean corpuscular volume (MCV), which is typically elevated in B12 deficiency, gradually normalises